The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design

BACKGROUND: Randomized controlled trials showed the nonvitamin K oral anticoagulant (NOAC) edoxaban was effective and safe for stroke and systemic embolism prevention in nonvalvular atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolism (VTE; including pulmonary embo...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Cardiol
Главные авторы: De Caterina, Raffaele, Agnelli, Giancarlo, Laeis, Petra, Unverdorben, Martin, Rauer, Heiko, Wang, Chun‐Chieh, Nakamura, Mashio, Chiu, Kuan‐Ming, Reimitz, Paul‐Egbert, Koretsune, Yukihiro, Chen, Cathy, Thee, Ulrike, Kaburagi, Jumpei, Kim, Young‐Hoon, Choi, Won‐Il, Yamashita, Takeshi, Cohen, Alexander, Kirchhof, Paulus
Формат: Artigo
Язык:Inglês
Опубликовано: Wiley Periodicals, Inc. 2019
Предметы:
Trial Designs
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906985/
https://ncbi.nlm.nih.gov/pubmed/31650560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.23279
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы